[{"id":"8ee6a642-903b-4775-8ffb-3149fa1ecff5","acronym":"ENESTFreedom","url":"https://clinicaltrials.gov/study/NCT01784068","created_at":"2021-01-17T17:35:07.021Z","updated_at":"2025-02-25T17:35:31.954Z","phase":"Phase 2","brief_title":"Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients","source_id_and_acronym":"NCT01784068 - ENESTFreedom","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 E255K • BCR-ABL1 Y253H","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 E255K • BCR-ABL1 Y253H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nilotinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 215","initiation":"Initiation: 03/04/2013","start_date":" 03/04/2013","primary_txt":" Primary completion: 05/31/2016","primary_completion_date":" 05/31/2016","study_txt":" Completion: 01/24/2025","study_completion_date":" 01/24/2025","last_update_posted":"2025-01-29"}]